So in ALS, rather than driving pathology, the baseline microbiome might be trying to counteract it, and losing key microbes removes that brake on microglial activation
If there is a risk of poor subject compliance with injections and/or a need for convenient administration, then researchers should certainly consider a BPC-157 + TB-500 nasal spray
Their GMP-manufactured purity and minimal-excipient formulation guarantee that your tissue-repair and inflammation-modulation data reflect peptide activitynot weighing inconsistencies or background noise
Establish baseline measurements before beginning treatment
So DSIP is not a guarantee. Its best framed as an experimental option that may fit a narrow set of cases
Importantly, -KG-deficient cells accumulate disulfide stress and exhibit disulfidptosis features under glucose starvation, which can be largely alleviated by AMPK restoration